Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Nash

Showing results (21-30 of 198) with videos related to

Pageof 20
Sort By:
Annals of the Rheumatic Diseases|March 6, 2021
Response to: 'Correspondence on 'Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement'' by Banday <i>et al</i>Peter Nash, Josef S Smolen
The Medical Journal of Australia|March 17, 2017
Advances in rheumatoid arthritisGraeme Jones, Peter Nash, Stephen Hall
Arthritis & Rheumatology (Hoboken, N.J.)|March 29, 2021
Current Treatment Strategies in Rheumatoid Arthritis After Methotrexate Are Not Enough to Maintain Sustained Remission: There Is No Holy Grail!Janet E Pope, Peter Nash, Roy Fleischmann
ACR Open Rheumatology|August 18, 2021
The Effect of Etanercept in Nonradiographic Axial Spondyloarthritis by Stratified C-Reactive Protein LevelsHoi Ki Joshua Tam, Peter Nash, Philip C Robinson
Therapeutic Advances in Musculoskeletal Disease|November 2, 2020
Choosing the right treatment for patients with psoriatic arthritisMaria Noviani, Marie Feletar, Peter Nash, et al.
Current Rheumatology Reports|July 21, 2022
Inhibiting IL-17A and IL-17F in Rheumatic Disease: Therapeutics Help to Elucidate Disease MechanismsHoi Ki Joshua Tam, Philip C Robinson, Peter Nash
The Journal of Rheumatology|August 1, 2023
Impact of COVID-19 on Patients With Psoriasis or Psoriatic ArthritisPhilip J Mease, Peter Nash, Suzanne Grieb, et al.
Annals of the Rheumatic Diseases|March 2, 2026
Response to 'Correspondence on 'Expert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 update' by Nash et al.' by Telliez et alPeter Nash, Andreas Kerschbaumer, Victoria Konzett, et al.
Dermatology (Basel, Switzerland)|March 22, 2006
Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS studyPeter Nash, Diamant Thaçi, Frank Behrens, et al.
Inflammatory Bowel Diseases|February 28, 2014
Stopping anti-TNF agents in patients with Crohn's disease in remission: is it a feasible long-term strategy?Dario Sorrentino, Peter Nash, Monica Viladomiu, et al.
Pageof 20

Showing results (21-30 of 198) with videos related to

Sort By:
Pageof 20
Annals of the Rheumatic Diseases|March 6, 2021
Response to: 'Correspondence on 'Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement'' by Banday <i>et al</i>Peter Nash, Josef S Smolen
The Medical Journal of Australia|March 17, 2017
Advances in rheumatoid arthritisGraeme Jones, Peter Nash, Stephen Hall
Arthritis & Rheumatology (Hoboken, N.J.)|March 29, 2021
Current Treatment Strategies in Rheumatoid Arthritis After Methotrexate Are Not Enough to Maintain Sustained Remission: There Is No Holy Grail!Janet E Pope, Peter Nash, Roy Fleischmann
ACR Open Rheumatology|August 18, 2021
The Effect of Etanercept in Nonradiographic Axial Spondyloarthritis by Stratified C-Reactive Protein LevelsHoi Ki Joshua Tam, Peter Nash, Philip C Robinson
Therapeutic Advances in Musculoskeletal Disease|November 2, 2020
Choosing the right treatment for patients with psoriatic arthritisMaria Noviani, Marie Feletar, Peter Nash, et al.
Current Rheumatology Reports|July 21, 2022
Inhibiting IL-17A and IL-17F in Rheumatic Disease: Therapeutics Help to Elucidate Disease MechanismsHoi Ki Joshua Tam, Philip C Robinson, Peter Nash
The Journal of Rheumatology|August 1, 2023
Impact of COVID-19 on Patients With Psoriasis or Psoriatic ArthritisPhilip J Mease, Peter Nash, Suzanne Grieb, et al.
Annals of the Rheumatic Diseases|March 2, 2026
Response to 'Correspondence on 'Expert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 update' by Nash et al.' by Telliez et alPeter Nash, Andreas Kerschbaumer, Victoria Konzett, et al.
Dermatology (Basel, Switzerland)|March 22, 2006
Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS studyPeter Nash, Diamant Thaçi, Frank Behrens, et al.
Inflammatory Bowel Diseases|February 28, 2014
Stopping anti-TNF agents in patients with Crohn's disease in remission: is it a feasible long-term strategy?Dario Sorrentino, Peter Nash, Monica Viladomiu, et al.
Pageof 20